Citation Impact
Citing Papers
Gout: On the brink of novel therapeutic options for an ancient disease
2004
A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications
2004
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
2002 Standout
New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression
2010
Early cyclosporine a withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: pathological study of graft biopsies at 1-year posttransplant
2002
Delayed graft function in kidney transplantation
2004 Standout
Severe Diarrhea in Renal Transplant Patients: Results of the DIDACT Study
2006
Glucose Metabolism in Renal Transplant Recipients
2005
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
2000 Standout
Pharmacokinetic Interactions Augment Toxicities of Sirolimus/Cyclosporine Combinations
2001
SIROLIMUS-INDUCED THROMBOCYTOPENIA AND LEUKOPENIA IN RENAL TRANSPLANT RECIPIENTS: RISK FACTORS, INCIDENCE, PROGRESSION, AND MANAGEMENT12
2000
Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools
2019
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
2002 Standout
WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1
2004
Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials
2006
Cellular pathophysiology of ischemic acute kidney injury
2011 Standout
Targeting mammalian target of rapamycin (mTOR) for health and diseases
2006
Rapamycin in transplantation: A review of the evidence
2001
A PILOT STUDY OF STEROID-FREE IMMUNOSUPPRESSION IN THE PREVENTION OF ACUTE REJECTION IN RENAL ALLOGRAFT RECIPIENTS
2001
A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS
2001
Long-Term Consequences of Kidney Donation
2009
Posttransplant Diabetes Mellitus in Kidney Transplant Recipients Receiving Calcineurin or mTOR Inhibitor Drugs
2006
Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient
2005
Gout
2009 Standout
The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway
2017
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
ESTABLISHMENT OF STABLE MULTILINEAGE HEMATOPOIETIC CHIMERISM AND DONOR-SPECIFIC TOLERANCE WITHOUT IRRADIATION1
2000
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
2008 Standout
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Cardiovascular Toxicities of Immunosuppressive Agents
2002
Diabetes Mellitus after Kidney Transplantation in the United States
2003 Standout
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery
2006 Standout
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
Induction of transplantation tolerance—the potential of regulatory T cells
2005
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
2001
Graft-versus-host disease
2009 Standout
The Science of Stewardship
2009
Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity
2004
Tuberous sclerosis
2008 Standout
De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years
2004
Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation
2003
Gout in Solid Organ Transplantation
2005
Type 1 diabetes
2013 Standout
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
2007 Standout
Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation
2005
Sirolimus(rapamycin) allows renal recovery in lung and heart transplant recipients with chronic renal impairment
2001
Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation
2008 Standout
Strategies to Improve Long-Term Outcomes after Renal Transplantation
2002 Standout
Prednisone‐Free Maintenance Immunosuppression—A 5‐Year Experience
2005
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
2005 Standout
MYCOPHENOLATE MOFETIL REDUCES LATE RENAL ALLOGRAFT LOSS INDEPENDENT OF ACUTE REJECTION
2000
Costimulation Blockade with Belatacept in Renal Transplantation
2005 Standout
A CALCINEURIN ANTAGONIST-FREE INDUCTION STRATEGY FOR IMMUNOSUPPRESSION IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS AT RISK FOR DELAYED GRAFT FUNCTION1
2001
Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen
2000 Standout
Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients
2003 Standout
Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
2008 Standout
The innate immune response in ischemic acute kidney injury
2008
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Uric acid and transplantation
2005
Effects of Sirolimus on Lipids in Renal Allograft Recipients: An Analysis Using the Framingham Risk Model
2002
Maintenance immunosuppression in the renal transplant recipient: An overview
2001
SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1
1999
The PI3K Pathway in Human Disease
2017 Standout
Infection in Solid-Organ Transplant Recipients
2007 Standout
Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids
2007
Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1
2003
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients
2008
Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery
2003 Standout
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
What's in the Pipeline? New Immunosuppressive Drugs in Transplantation
2002
Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background
2000
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
2008 Standout
Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion
2009 StandoutNobel
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation
2004
Ethnic and Gender Related Differences in the Risk of End-Stage Renal Disease After Living Kidney Donation
2011
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1
2002
Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
2000 Standout
Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence
2012
SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10
2001
Dendritic cells with TGF-β1 differentiate naïve CD4+CD25−T cells into islet-protective Foxp3+regulatory T cells
2007 StandoutNobel
Magnesium in Man: Implications for Health and Disease
2014 Standout
Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease
2002
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Correlative imaging of ionic transport and electronic structure in nano Li0.5FePO4 electrodes
2019 StandoutNobel
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
2006
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents
2001
Tissue Engineering--Current Challenges and Expanding Opportunities
2002 StandoutScience
Exercise training for adults with chronic kidney disease
2011
Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression
2009
Delayed Wound Healing with Sirolimus after Liver Transplant
2002
Risk of End-Stage Renal Disease Following Live Kidney Donation
2014 Standout
Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries
2001
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
2004
Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and Insulin on Initiation Factor 4E-Binding Proteins
2005 StandoutNobel
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
2000
Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton Protocol
2001 Standout
Works of Lars Wramner being referenced
A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION
1999
SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12
2000
Sirolimus Does Not Exhibit Nephrotoxicity Compared to Cyclosporine in Renal Transplant Recipients
2002
SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATION
1999 Standout
Incidence of End-Stage Renal Disease Among Live Kidney Donors
2006
Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the sirolimus European renal transplant study
2003
A Comparative, Randomized Trial of Concentration-Controlled Sirolimus Combined With Reduced-Dose Tacrolimus or Standard-Dose Tacrolimus in Renal Allograft Recipients
2013
Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy
2010
Physical performance does not improve in elderly patients following successful kidney transplantation
1995
SIROLIMUS VERSUS CYCLOSPORINE IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL.
2000